Sarepta Therapeutics (SRPT) EBITDA Margin (2012 - 2026)

Sarepta Therapeutics' EBITDA Margin history runs 13 years deep, the most recent figure standing at 89.54% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 31483.0% year-over-year to 89.54%; the TTM figure through Mar 2026 stood at 1.94% (up 396.0% YoY), while the FY2025 annual figure was 31.83%, down 4330.0% from the prior year.
• EBITDA Margin was 89.54% for Q1 2026 at Sarepta Therapeutics, up from 92.92% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 89.54% in Q1 2026 to a low of 478.58% in Q1 2022.
• Historically, EBITDA Margin has averaged 76.0% across 5 years, with a median of 44.99% in 2025.
• The sharpest annual moves came in 2022 and 2026: EBITDA Margin tumbled 36474 bps in 2022, then surged 31483 bps in 2026.
• A 5-year view of EBITDA Margin shows it stood at 63.66% in 2022, then surged by 116 bps to 10.19% in 2023, then surged by 141 bps to 24.56% in 2024, then sank by 478 bps to 92.92% in 2025, then soared by 196 bps to 89.54% in 2026.
• The last three EBITDA Margin figures came in at 89.54% (Q1 2026), 92.92% (Q4 2025), and 44.99% (Q3 2025), per Business Quant data.